Efficacy and Safety of Aviron Rapid® in 18-60-year-old Patients with Clinical Diagnosis of Acute Respiratory Viral Infection: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Georgi Popov¹, Margarita Gospodinova-Bliznakova², Zlatko Kalvatchev³, Andrey Tchorbanov⁴

¹ Department of Infectious Diseases, Military Medical Academy of Sofia, Sofia, Bulgaria
² Department of Infectious Diseases, Parasitology and Dermatovenerology, Medical University of Varna, Varna, Bulgaria
³ Virology Laboratory, MBAL Nadezhda, Sofia, Bulgaria
⁴ Laboratory of Experimental Immunology, Stefan Angelov Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria

Corresponding author: Andrey Tchorbanov, Laboratory of Experimental Immunology, Stefan Angelov Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria; E-mail: atchorbanov@yahoo.com; Tel.: +359 2 979 6357

Received: 14 Feb 2021 ♦ Accepted: 22 Feb 2021 ♦ Published: 28 Feb 2021

Citation: Popov G, Gospodinova-Bliznakova M, Kalvatchev Z, Tchorbanov A. Efficacy and safety of Aviron Rapid® in 18-60-year-old patients with clinical diagnosis of acute respiratory viral infection: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Folia Med (Plovdiv) 2021;63(1):129-37. doi: 10.3897/folmed.63.e64415.

Abstract

Aim: Prevention and treatment of upper respiratory tract infections are given the highest priority because of the tremendous health and economic impact of these diseases. Development of novel effective and safe options for treatment can contribute considerably to decrease the burden of disease.

Materials and methods: We designed a multicenter, randomized, double-blind, placebo-controlled study in ambulatory-treated adult patients with a clinical diagnosis of acute upper respiratory tract viral infection. The patients (18-60 years old) were randomized into two groups and followed-up for 5 days. Group 1 received the standard symptomatic therapy + Aviron Rapid®, and Group 2 received the standard symptomatic therapy + placebo. The primary endpoint of the study was defined as the duration of disease measured by the percentages of disease-free patients for every 12-hour period of the study.

Results: Treating clinically relevant patients with the natural product Aviron Rapid® for 5 days decreases the duration of disease, the intake of antipyretics and the severity of symptoms. Significant difference between the tested groups for most of studied parameters was found as soon as 12 or 24 hours after initiation of administration in favour of active arm and was the most prominent on days 3 and 4. Significant decrease in the total score of symptoms severity was achieved on day 4 and extended to the end of study. There were no differences in the adverse events between the groups and the tested product demonstrated excellent safety profile.

Conclusions: This study is a clinical confirmation of well documented antiviral activity of the product targeting multiple points in viral replication and covering broad spectrum viral pathogens.

Keywords
antiviral, Aviron Rapid®, treatment, upper respiratory tract infection
INTRODUCTION

Acute upper respiratory tract infections (URTIs) are the most common infectious pathology in routine clinical practice. The high incidence, between 2-5 episodes and 7-10 episodes per year in adults and in school-age children, respectively, can be explained by the easy airdrops transmission, relatively short incubation period and short-lasting specific immunity after acute illness. Acute URTIs are the most common reason for physician office visits; they have tremendous impact on quality of life representing significant amount of direct and indirect healthcare costs. Therefore, prevention and control of URTIs are the main clinical targets with significant health and economic impact.

Virus etiology of URTIs is reported to be between 40% and 90% globally and more than 80% of URTIs in children are related to different viruses. To date, more than 200 viruses have been identified as causative agents for URTIs. They can be mainly grouped in one-family DNA viruses (Adenoviridae), and four-families RNA viruses (Orthomyxoviridae, Paramyxoviridae, Picornaviridae и Coronaviridae).

In the daily clinical practice, diagnosis is usually empirical and based on clinical signs. Lack of information about the disease etiology and lack of specific treatment for most of viral pathogens, necessitate nonspecific, most commonly symptomatic treatment only.

Symptoms relief is the main aim of empiric URTIs treatment. Despite the many symptomatic remedies providing temporary relief of symptoms, there is no available evidence that they shorten time for symptom alleviation. Antibiotics are not effective against viral pathogens and are not recommended for prevention of secondary bacterial infections in immunocompromised patients. Another approach to managing the URTIs is the usage of immunomodulators. Some of them stimulate interferones secretion, others, like inosine acedoben dimepranol, have positive effect on different immune responses in vitro and in vivo. Still the available data of its effectiveness for prevention and treatment of URTIs are inconclusive and inconsistent.

Despite of the revolutionary progress of medical science, the treatment of viral URTIs remains a significant challenge. Very few antiviral drugs have been established as a routine URTIs approach in daily outpatient clinical practice. Those are the M2 channel blockers (amantadine and rimantadine) that demonstrated effectiveness against influenza A virus only, and neuraminidase inhibitors (oseltamivir and zanamivir), with activity against influenza A and B viruses. Another challenge for viral URTIs treatment is the lack of proven effect against flu-like illness, defined as presence of two or more symptoms, including nasal congestion, headache, chills/sweating, sore throat, cough, fatigue, myalgia, and fever. Frequent mutations of influenza virus has also led to considerable resistance to M2 channel blockers making their effectiveness questionable. All those challenges clearly defined the need of new therapeutic options for treatment of viral URTIs, including alternative ones, with potential broad spectrum antiviral efficacy against pathogens responsible for most common URTIs and real implications for clinical practice.

AIM

The aim of current clinical trial is to evaluate the effect of Aviron Rapid®, registered as food supplement in adult patients with clinical diagnosis of viral URTI and treated according to usual clinical practice. Aviron Rapid® is a combination of three well studied and clinically tested active ingredients: proprietary humic acid racemic mixture, proprietary spirulina extract, and andrographolide.

MATERIALS AND METHODS

Treatment options

Group 1 - Aviron Rapid®. Every 647 mg tablet contains 10 mg andrographolide, 100 mg proprietary extract from spirulina and 250 mg proprietary humic acid racemic mixture.

Group 2 - placebo available as exactly the same 647 mg white tablets in same package as Group 1.

Every package had a unique number generated by randomization software. Dosage of investigated product and placebo was as specified by manufacturer. Day 1: 3 times × 3 tablets; day 2: 3 times × 2 tablets; day 3 to day 5: 3 times × 1 tablet/daily.

Study review

A multicenter, randomized, double-blind, placebo-controlled study was performed in 85 outpatient centres. Informed consent was obtained in all cases. The study was conducted according to the Declaration of Helsinki. First patient was enrolled on 27.01.2020 and last patient was completed on 09.03.2020. Two clinical assessments were made by participating physicians – on day 1 (initiation) and day 6 (closing visit). From the evening of day 1 to the morning of day 6 the patients assessed their symptoms in a diary at every 12 hours.

Selection of patients

Patients were enrolled in the study based on inclusion and exclusion criteria. Inclusion criteria: 18-60 years old ambulatory-treated patients with a clinical diagnosis of acute upper respiratory tract viral infection with: axillary temperature >37°C and one or more of the following symptoms: nasal congestion, cough, sore throat, headache, fatigue, and sleep disturbances. The symptoms should be present no more than 24 hours before examination. Exclusion criteria: treatment with inosine acedoben dimepranol, rimantadine hydrochloride, neuraminidase inhibitors - oseltamivir, zanamivir; suspected bacterial infection, pneumonia or other, that have to be treated with antibiotics; clinical symptoms of severe flu/acute URTI needed hospitalization; initial symptoms similar to URTI but related to different
diseases (other infectious diseases, flu-like syndrome in systemic connective tissue disease, onco-hematologic and other diseases); medical history for primary or secondary immune deficiencies; medical history of sarcoidosis; diabetes or serious chronic diseases of heart, liver, kidney or brain; cancer; exacerbation or decompensation of chronic disease affecting ability to participate in the clinical trial; medical history of allergy; allergy/intolerance to some of ingredients of the tested product; patients with malabsorption including congenital or acquired lactase or other disaccharidase deficit; patients with galactosemia; drug addicted patients; consumption of 2 or more alcohol units per day; patients with psychiatric disease; patients participating in another clinical study in the last 3 months. All patients that started antibiotic treatment during the study were also excluded from data analysis.

**Baseline data**

A total number of 778 patients were included in the study (Group 1, n=390, and Group 2, n=388). After randomization, 162 patients were excluded from final data analysis (Fig. 1). All demographic and clinical parameters were comparable between treated and control groups. Average age of participants was 39.27 years; females were 60.7% of the study population (Table 1). There was no significant difference between groups in mean axillary temperature and total score for severity of symptoms (Table 2).

**Patient evaluation**

Clinical evaluation on day 1 included: measurement of axillary temperature, physical examination, and symptoms assessment. Severity of every symptom was evaluated by a visual analogue scale (VAS) where 0 indicates lack of symptoms, 1-2 = very mild symptoms, 3-4 = mild, 5-6 = moderate, 7-8 = severe, 9 = very severe, and 10 indicates extraordinary severe symptoms. Clinical evaluation on day 6 included: measurement of axillary temperature, physical examination, and general evaluation of patients’ condition ticked as healthy or ill. If during the study, a patient became worse, a second clinical assessment was made before day 6,

---

**Figure 1.** Scheme of patient randomization and distribution and the experimental therapeutic design.
and the date, the reason for examination, new treatment or hospitalization were registered in the protocol. All patients received a diary and filled the data for axillary temperature, VAS score of symptoms and non-steroid anti-inflammatory drugs (NSAIDs) intake.

**Treatment**

The patients who met the study criteria were randomized by Randomsamp software and were allocated to one of the following treatment groups: Group 1: standard symptomatic therapy + Aviron Rapid®, Group 2: standard symptomatic therapy + placebo. The following drugs were used as a standard symptomatic treatment: NSAIDs, decongestants, bronchodilators, mucolytics, antitussives and other drugs for treatment of chronic diseases. Use of other antiviral remedies, antihistamines, antibiotics, and interferons was not allowed. Usage of NSAIDs and other symptomatic drugs was recorded in physician protocols and patient diaries.

**Efficacy endpoints**

Primary endpoint of the study was defined as duration of disease measured by the percentage of disease-free patients for every 12-hour period of the study. Disease-free patient was defined as follows: lasting improvement of every symptom to score “very mild” or “lack of symptoms” (severity ≤ 2 points) and the summary score of all symptoms must be ≤ 12 points; lasting decrease of axillary temperature to <37.0°C. Lasting decrease was defined as a temperature <37.0°C in two consecutive 12-hour periods measurements and not measured again ≥37.0°C to the end of study; measured axillary temperature <37.0°C must be without concomitant intake of antipyretics;

Secondary endpoints are defined as follows: percentages of patients with lasting decrease of temperature <37.0°C; time to lasting decrease of temperature <37.0°C; decrease of the number of patients taking antipyretics; time on antipyretic treatment; decrease of severity of symptoms; percentage of patients with lasting relief of every single symptom (nasal congestion, cough, sore throat, headache, fatigue, sleep disturbances).

**Statistical analysis**

This study was based on parallel group design with superiority hypothesis. For equality of means, parametric independent samples T test was used. For difference of relative parts of two samples in one-side critical area a Z-test was used. A one-tailed probability value $p \leq 0.05$ was considered statistically significant. All statistical evaluations were done using SPSS 17 and STATA 10.1.

**Safety analysis**

Safety was evaluated in all patients completed the study in both treated and control groups, included in data analysis, and received at least one dose of Aviron Rapid® ($n=307$) or placebo ($n=309$). All registered adverse events (AE) and results of physical examination are summarized in a table by treatment group.

**RESULTS**

**Primary endpoint**

Statistically significant difference was found 24 hours after initiation of treatment in the relative number of disease-free patients in favour of Group 1 ($p<0.01$). On day 3, significantly more patients in Group 1 (20.5%, $n=97$)
were disease-free vs. patients receiving placebo (8.4%, n=56) (p<0.01). The difference between treatment groups remained significant to the end of study in favour of Group 1 (91.2%, n=280) vs. Group 2 (82.8%, n=256) (p<0.01) (Fig. 2). Average time of disease in Group 1 was 77 hours, vs. 87 hours in Group 2 (p<0.001).

Secondary endpoints

**Lasting decrease of temperature**

Patients in Group 1 demonstrated significantly faster and lasting decrease of axillary temperature below 37.0°C (p<0.001). As soon as 24 hours after beginning of treatment, significantly more patients in Group 1 (p<0.001) had temperature <37.0°C compared to Group 2 and this difference remained significant for all measured points of the study. On day three, 73% more patients in Group 1 (47.9%, n=147) had temperature <37.0°C measured in 2 consecutive 12-hour periods vs Group 2 – 27.5% (n=85) (p<0.001). Average time of patients with fever was 66 hours in Group 1 vs. 79 hours in Group 2 (p<0.001) (Fig. 3).

**Decrease the number of patients taking antipyretics**

Significantly lower number of patients taking antipyretics were found in Group 1 compared to Group 2, reaching significance 12 hours after initiation of treatment (p<0.05). The difference remained significant through all periods of study, with maximal value on day 3 – Group 1, 14.3% (n=44) vs. Group 2, 58.6% (n=181) (p<0.001). Average time of antipyretics intake was also significantly lower in Group 1 - 44 hours vs. 68 hours in Group 2 (p<0.001) (Fig. 4).

**Decrease of symptoms severity**

The total score of all evaluated symptoms reached statistical significance in favour of Group 1 vs. Group 2 starting from day 4 (p<0.021). The significance of observed benefit in Group 1 remained unchanged till the end of study (p<0.001) on day 5 (Table 3). The same trend was observed for the VAS score of every individual score for 3 of symptoms, included as secondary endpoint – nasal congestion, cough, and sore throat. However, starting from day 4, significant difference (p<0.0027) was observed in all remaining periods to the end of study only for the sore throat symptom. At the end of study 3.8% of patients in Group 1 (n=11) reported sore throat symptom vs. 7.5% in Group 2 (n=23) (p<0.0267). Statistically significant differences were not observed between the study groups for the other 3 individual symptoms included in the assessment (headache, fatigue, and sleep disturbances).

![Figure 2](image-url)  
**Figure 2.** Percentage of disease-free patients at every 12-hours period in studied groups. Solid line represents patients in group 1, dotted line – patients in group 2. Significant difference was reached 24 hours after inclusion (p<0.01), and present for every period to the end of study (p<0.01 at last observed period).
Figure 3. Average duration of fever in hours (66 in group 1 vs 79 in group 2, p<0.001), measured by time to lasting (sustainable for more than two consecutive 12-hours periods and lasting to the end of study), decrease of temperature <37.0°C.

Table 3. Symptom severity at every period

| Time period          | Group 1 | Group 2 | p-Value† |
|----------------------|---------|---------|----------|
|                      | n=307   | n=309   |          |
| Day 1 inclusion      | 27.77   | 27.15   | 0.449    |
| Day 1 - evening      | 28.66   | 29.03   | 0.673    |
| Day 2 - morning      | 24.70   | 25.81   | 0.213    |
| Day 2 - evening      | 21.05   | 22.20   | 0.190    |
| Day 3 - morning      | 15.91   | 17.05   | 0.144    |
| Day 3 - evening      | 13.16   | 14.54   | 0.057    |
| Day 4 - morning      | 9.39    | 10.76   | 0.021    |
| Day 4 - evening      | 7.15    | 8.84    | 0.002    |
| Day 5 - morning      | 4.74    | 6.23    | 0.001    |
| Day 5 - evening      | 3.14    | 4.73    | <0.001   |

† - Sig. (2-tailed) t-test for Equality of Means

Figure 4. Average duration of antipyretics intake (44 in group 1 vs 68 in group 2, p<0.001), measured by time to lasting (sustainable for more than two consecutive 12-hours periods and lasting to the end of study), antipyretics-free periods.

Table 4. Adverse events reported

| SERIOUS ADVERSE EVENTS                  | Group 1 (n=390) | Group 2 (n=388) |
|-----------------------------------------|-----------------|-----------------|
| Reported (n)                           | Reported (%)    | Reported (%)    |
| Serious adverse events reported        | 0               | 0%              |

ANY ADVERSE EVENTS

|                        | Group 1 (n=390) | Group 2 (n=388) |
|------------------------|-----------------|-----------------|
| Reported (n)           | Reported (%)    | Reported (%)    |
| Alergic reaction       | 0               | 0.00%           |
| Hospitalization        | 1               | 0.30%           |
| Shingles               | 2               | 0.50%           |
| Antibiotic treatment unknown reason | 33             | 7.90%           |
| Bronchitis             | 3               | 0.80%           |
| Laryngitis             | 0               | 0.00%           |
| Acute tonsillitis      | 0               | 0.00%           |
| Sinusitis              | 0               | 0.00%           |
| TOTAL ADVERSE EVENTS   | 39              | 10.00%          |

Tolerance and safety assessment

No allergic reactions or allergy exacerbations was reported in the Group 1 vs one reported in the placebo group. No drug interaction was observed in both groups in concomitant use of standard care – NSAIDs, decongestants, bronchodilators, mucolytics, and drugs used for treatment of chronic diseases. One patient from Group 1 was hospitalized (Table 4). In the current study, Aviron Rapid® demonstrated excellent safety profile comparable with placebo group and lack of drug interactions.
DISCUSSION

Prevention and treatment of URTIs are among the most important targets for scientists because of their tremendous impact on society. URTIs are significant burden for healthcare and economy for each country. Despite the tremendous efforts of army of scientists and huge amounts of allocated resources, there are several challenges keeping progress slow and unsatisfactory. The main challenge is that most of URTIs are caused by viruses – a very tough therapeutic target. Up to date very few antiviral agents are available for routine use in daily outpatient clinical practice – neuraminidase inhibitors and M2 channel blockers. The problem is that they have demonstrated an effect only against influenza virus - a small portion of more than 200 viral pathogen causing URTIs.

Our study addresses some of the issues by different, alternative approach based on a natural therapeutic product, supported by relevant scientific data. The targets are the most common URTIs with unknown etiology treated routinely in outpatient GP practice. Some reports suggest the broad spectrum antiviral activity of active ingredients in vitro and in vivo against common viral pathogens: Influenza A14-16, Influenza B14, Coxsackie A917, Coxsackievirus A18, Coxsackievirus B414, Adenovirus type 718, RSV19, CMV14,17, EBV20, HSV-121-22, HSV-214, Astrovirus 1, Rotavirus Wа, and Adenovirus 4018. This combination has potential synergic effect and targets different stages of virus replication in host cells: inhibits attachment of the virus to the cell surface17; suppresses fusion of virus envelope with endosomal membrane by structural change of tripeptide sequence Phe-Leu-Gly on virus envelope glycoproteins19; inhibits endonuclease activity of viral RNA-polymerase15 and intracellular transportation of viral particles23. Published data from randomized clinical trials and systematic reviews demonstrates promising evidence for efficacy of active ingredients in patients with flu, common cold and URTIs. The study we performed is a step further to test active ingredients in patients with flu, common cold and URTIs.

The study was supported by Neopharm Bulgaria Ltd. The study was supported by Neopharm Bulgaria Ltd.

REFERENCES

1. Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 2005; 5(11):718–25.
2. Abed Y, Boivin G. Treatment of respiratory virus infections. Antiviral Res 2006; 70(2):1–16.
3. Ashworth M, Latinovic R, Charlton J, et al. Why has antibiotic prescribing for respiratory illness declined in primary care? A longitudinal study using the General Practice Research Database. J Public Health (Oxf) 2004; 26(3):268–74.
4. Georgieva I, Angelova S, Korsun N. Viral etiology of acute respiratory infections among children under 5 years of age in Bulgaria, during the 2013/2014 and 2014/2015 seasons. Trakia Journal of Sciences 2015; 13(2):55–60.
5. Cotton M, Innes S, Jaspan H, et al. Management of upper respiratory tract infections in children. S Afr Fam Pract 2008; 50(2):6–12.
6. Petersen I, Johnson AM, Islam A, et al. Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database. BMJ 2007; 335(7627):982.
7. Rumel Ahmed S, Newman AS, O’Daly J, et al. Inosine Acedoben Dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications. Int Immunopharmacol 2017: 42: 108–14.
13. World Health Organization. WHO. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: M2 ion channel inhibitor. Available from: https://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/m2inhibitor/en/. Accessed January 19, 2021.

14. Karkos PD, Leong SC, Karkos CD, et al. Spirulina in clinical practice: evidence-based human applications. Evid Based Complement Alternat Med 2011; 2011:531053.

15. Lu FJ, Tseng SN, Li ML, et al. In vitro anti-influenza virus activity of synthetic humate analogues derived from protocatechuic acid. Arch Virol 2002; 147(2):273–84.

16. Gupta S, Mishra KP, Ganju L. Broad-spectrum antiviral properties of andrographolide. Arch Virol 2017; 162(3):611–23.

17. Klöcking R, Helbig B. Medical aspects and applications of humic substances. In: Biopolymers Online. Wiley-VCH Verlag GmbH & Co. KGaA; 2005.

18. El-Baz F, El-Senousy WM, El-Sayed AB, et al. In vitro antiviral and antimicrobial activities of Spirulina platensis extract. J Appl Pharm Sci 2013; 3(12):52–6.

19. Hosoya M, Balzarini J, Shigeta S, et al. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob Agents Chemother 1991; 35(12): 2515–20.

20. Lin T-P, Chen S-Y, Duh P-D, et al. Inhibition of the Epstein-Barr virus lytic cycle by andrographolide. Biol Pharm Bull 2008; 31(11): 2018–23.

21. Klöcking R, Helbig B. Interaction of humic acids and humic-acid-like polymers with herpes simplex virus type 1 BT. In: Allard B, Borén H, Grimvall A, eds. Humic substances in the aquatic and terrestrial environment. Berlin, Heidelberg: Springer Berlin Heidelberg; 1991.

22. Aromdee C, Suebsasana S, Ekalaksananan T, et al. Stage of action of naturally occurring andrographolides and their semisynthetic analogues against herpes simplex virus type 1 in vitro. Planta Med 2011; 77(9):915–21.

23. Xia Y-F, Ye B-Q, Li Y-D, et al. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 2004; 173(6): 4207–17.

24. Hu X-Y, Wu R-H, Logue M, et al. Andrographis paniculata (Chuan Xin Lián) for symptomatic relief of acute respiratory tract infections in adults and children: a systematic review and meta-analysis. PLoS One 2017; 12(8):e0181780.

25. Jankowski A, Nienartowicz B, Polanska B, et al. A randomised, double-blind study on the efficacy of Tolpa Torf Preparation (TTP) in the treatment of recurrent respiratory tract infections. Arch Immunol Ther Exp (Warsz) 1993; 41(1):95–7.
Efficacy and Safety of Aviron Rapid® in Adult Patients

Efficacy and Safety of Aviron Rapid® in Adult Patients

Folia Medica I 2021 I Vol. 63 I No. 1

Эффективность и безопасность Aviron Rapid® у пациентов в возрасте 18–60 лет с клиническим диагнозом острой респираторной вирусной инфекции: многоцентровое рандомизированное двойное слепое плацебо-контролируемое клиническое исследование

Георги Попов, Маргарита Господинова-Близнакова, Златко Калвачев, Андрей Чорбанов

1 Кафедра „Инфекционные болезни“, Военно-медицинская академия - София, София, Болгария
2 Кафедра „Инфекционные болезни, паразитология и дерматовенерология“, Медицинский университет - Варна, Варна, Болгария
3 Вирусологическая лаборатория, МБАЛ „Надежда“, София, Болгария
4 Лаборатория экспериментальной иммунологии, Институт микробиологии „Степан Ангелов“, Болгарская академия наук, София, Болгария

Адрес для корреспонденции: Андрей Чорбанов, Лаборатория экспериментальной иммунологии, Институт микробиологии им. Стефана Ангелова, Болгарская академия наук, 1113, София, Болгария; E-mail: atchorbanov@yahoo.com; Тел.: +359 2 979 6357

Дата получения: 14 февраля 2021 * Дата приемки: 22 февраля 2021 * Дата публикации: 28 февраля 2021

Образец цитирования: Popov G, Gospodinova-Bliznakova M, Kalvatchev Z, Tchorbanov A. Efficacy and safety of Aviron Rapid® in 18-60-year-old patients with clinical diagnosis of acute respiratory viral infection: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Folia Med (Plovdiv) 2021;63(1):129-37. doi: 10.3897/folmed.63.e64415.

Резюме

Цель: Профилактика и лечение инфекций верхних дыхательных путей имеют наивысший приоритет из-за огромного воздействия этих заболеваний на здоровье и экономику. Разработка новых эффективных и безопасных вариантов лечения может существенно снизить бремя болезни.

Материалы и методы: Мы провели многоцентровое рандомизированное двойное слепое плацебо-контролируемое исследование с участием взрослых пациентов, находящихся на амбулаторном лечении с клиническим диагнозом острой вирусной инфекции верхних дыхательных путей. Пациенты (в возрасте от 18 до 60 лет) были случайным образом разделены на две группы и наблюдались в течение 5 дней. Группа 1 получала стандартную симптоматическую терапию плюс Aviron Rapid®, а группа 2 получала стандартную симптоматическую терапию плюс плацебо. Конечная точка исследования определялась как продолжительность заболевания, измеряемая процентом пациентов, не затронутых заболеванием, в течение каждого 12-часового периода исследования.

Результаты: Лечение соответствующих пациентов натуральным продуктом Aviron Rapid® в течение 5 дней уменьшило продолжительность заболевания, приём жаропонижающих средств и тяжесть симптомов. Значительная разница между исследуемыми группами по большинству изучаемых параметров была обнаружена через 12 или 24 часа после начала приёма в пользу активной группы и была наиболее выражена на 3-й и 4-й дни. Значительное снижение общей оценки тяжести симптомов была достигнута в течение 4-го дня и продолжалась до конца исследования. Не было различий между побочными эффектами между группами, и протестированный продукт показал отличный профиль безопасности.

Заключение: Это исследование является клиническим подтверждением хорошо задокументированной противовирусной активности продукта, который нацелен на многие моменты репликации вируса и охватывает широкий спектр вирусных патогенов.

Ключевые слова

противовирусный, Aviron Rapid®, лечение, инфекции верхних дыхательных путей